Clinical Trial

Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration

Study acronym: PBM in iAMD
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study evaluates whether a low-energy laser treatment called photobiomodulation (PBM) can improve visual function and retinal structure in patients with age-related macular degeneration (AMD) who have reticular pseudodrusen. PBM is a non-invasive therapy that uses specific wavelengths of light to stimulate cellular activity and reduce inflammation without causing tissue damage. Participants will be randomly assigned to receive either active PBM treatment or a sham (inactive) treatment. The study will assess changes in visual performance under low-light conditions and retinal structure over a 12-month period. The goal is to determine whether PBM can slow disease progression and improve visual function in patients with early stages of AMD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-21.
Trial Details
NCT Number NCT07554690
Lead Sponsor Fondazione G.B. Bietti, IRCCS
Conditions AMD - Age-Related Macular Degeneration
Enrollment 67 participants
Start Date 2026-06-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04